Saving changes...

Done

Error

Drug-Induced Cardiotoxicity of Oncological Agents: Monitoring Parameters, Prevention, and Future Chemotherapy

Drug-Induced Cardiotoxicity of Oncological Agents: Monitoring Parameters, Prevention, and Future Chemotherapy

Drug-Induced Cardiotoxicity of Oncological Agents: Monitoring Parameters, Prevention, and Future Chemotherapy

Industry Specialist
Industry Specialist
on behalf of International Academy Of Compounding Pharmacists

$15.00 $ 15.00 $ 15.00

$15.00 $ 15.00 $ 15.00

$ 15.00 $ 15.00 $ 15.00
$ 15.00 $ 15.00 $ 15.00
Normal Price: $15.00 $15.00

Review:

Launch date: 10 Mar 2017
Expiry Date:

Last updated: 13 Mar 2017

Reference: 171732

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

You have null days left.

Description

A comprehensive presentation on: Drug-Induced Cardiotoxicity of Oncological Agents: Monitoring Parameters, Prevention, and Future Chemotherapy

Objectives

Objectives
At the completion of this activity, the pharmacist will be able to:
Determine the clinical significance of cardiotoxicity in cancer therapy.
Describe the mechanism of action and cardiotoxic effects of anthracyclines, mitoxantrone, trastuzumab, 5-fluorouracil, and bortezomib.
Compare the cardiotoxicity safety profiles of the different HER2 inhibitors and their roles in HER2 positive breast cancer
Evaluate the treatment options, monitoring parameters, and prevention of anti-cancer drug-induced cardiotoxicity.

At the completion of this activity, the technician will be able to:
Describe the clinical significance of cardiotoxicity in cancer therapy.
Describe the mechanism of action and cardiotoxic effects of anthracyclines, mitoxantrone, trastuzumab, 5-fluorouracil, and bortezomib.
Compare the cardiotoxicity safety profiles of the different HER2 inhibitors and their roles in HER2 positive breast cancer
Describe the treatment options, monitoring parameters, and prevention of anti-cancer drug-induced cardiotoxicity.
Industry Specialist

Author Information Play Video Bio

Industry Specialist
on behalf of International Academy Of Compounding Pharmacists

The International Academy of Compounding Pharmacists is the recognized authority for information, expertise, and practice standards with regard to pharmacy compounding.

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Accreditation Council for Pharmacy Education (ACPE)
  • 1.00 Hours -
    Exam Pass Rate: 75

Faculty and Disclosures

Additional Contributors

Additional Contributors can be optionally entered here

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error